Dr. Ugarte-Gil is an Associate Professor at the Department of Epidemiology at SPPH at UTMB. He has PhD in Global Diseases Epidemiology and Control from Johns Hopkins Bloomberg School of Public Health, a MSc in Epidemiology at London School of Hygiene and Tropical Medicine and MD from Universidad Peruana Cayetano Heredia.

Dr. Ugarte-Gil's work is focused on respiratory infections such as Tuberculosis, COVID-19, Influenza and others. His interest is validation of point-of-care diagnostic tools and their implementation at primary care level. Also, he has a specific interest in the association of comorbidities such as diabetes mellitus and depression with tuberculosis, and how this association can affect tuberculosis treatment outcomes. Another interest is research in Bartonella bacilliformis, a bacterial infection common in the Andean region, and other common tropical infections prevalent in Latin America. He has also served as an member of the Expert Board at the National Tuberculosis Program in Peru, independent consultant for PAHO and WHO in Tuberculosis.

• PhD, Global Diseases Epidemiology and Control, The Johns Hopkins University, US, 2017
• MSc Epidemiology, London School of Hygiene and Tropical Medicine, UK, 2009
• MD, Universidad Peruana Cayetano Heredia, Perú , 2005

Research Articles in Peer Reviewed Journals:

• Koeppel L, Denkinger CM, Wyss R, Broger T, Chegou NN, Dunty JM, Scott K, Cáceres T, Dutoit E, Ugarte-Gil C, Nicol M, Gotuzzo E, Corstjens PLAM, Geluk A, Sutherland J, Sigal GB, Moreau E, Albertini A, Mantsoki A, Ongarello S, Walzl G, Fernandez Suarez M. Diagnostic performance of host protein signatures as a triage test for active pulmonary TB. J Clin Microbiol. 2023 Sep 19;:e0026423. doi: 10.1128/jcm.00264-23. 
• Caceres-Cardenas G, Ruiz-Grosso P, Ugarte-Gil C. Challenges in the management of depressive disorders comorbid with tuberculosis and type 2 diabetes. Curr Opin Psychiatry. 2023 Sep 1;36(5):360-365. doi: 10.1097/YCO.0000000000000885. Epub 2023 Jul 10. 
• Faust L, Naidoo P, Caceres-Cardenas G, Ugarte-Gil C, Muyoyeta M, Kerkhoff AD, Nagarajan K, Satyanarayana S, Rakotosamimanana N, Grandjean Lapierre S, Adejumo OA, Kuye J, Oga-Omenka C, Pai M, Subbaraman R. Improving measurement of tuberculosis care cascades to enhance people-centred care. Lancet Infect Dis. 2023 Aug 28;. doi: 10.1016/S1473-3099(23)00375-4. 
• Ruiz-Grosso P, Loret de Mola C, Otero L, Ugarte-Gil C. Are trajectories of depressive symptoms during the first half of drug-sensitive pulmonary tuberculosis treatment associated with loss to follow-up? A secondary analysis of longitudinal data. BMJ Open. 2023 Jul 19;13(7):e068235. doi: 10.1136/bmjopen-2022-068235. PubMed PMID: 37474177; 
• Calderon-Flores R, Caceres-Cardenas G, Alí K, De Vos M, Emperador D, Cáceres T, Eca A, Villa-Castillo L, Albertini A, Sacks JA, Ugarte-Gil C. Diagnostic performance of four lateral flow immunoassays for COVID-19 antibodies in Peruvian population. PLOS Glob Public Health. 2023; 3(6):e0001555.
• MacLean EL, Villa-Castillo L, Espinoza-Lopez P, Caceres T, Sulis G, Kohli M, Pai M, Ugarte-Gil C. Integrating tuberculosis and COVID-19 molecular testing in Lima, Peru: a cross-sectional, diagnostic accuracy study. Lancet Microbe. 202; 4(6):e452-e460.
• Paredes JL, Picon V, Reynolds L, Ugarte-Gil C, Moore D. Impact of the COVID-19 pandemic on TB care in Peru. Int J Tuberc Lung Dis. 2023; 27(5):411-413.
• Palomino-Padilla S, Finch L, de Vos M, Savage H, Villa-Castillo L, Hayward G, Cook E; LSTM diagnostics group; UTB-IMTAvH group; CONDOR steering group; Escadafal C, Body R, Adams ER, Ugarte-Gil C, Cubas-Atienzar AI. Diagnostic performance of GENEDIA W and ActiveXpress+ COVID-19 antigens tests among symptomatic individuals in Peru and The United Kingdom. PLoS One. 2023; 18(3):e0281925.
• Llanos-Cuentas A, Schwalb A, Quintana JL, Delfin B, Alvarez F, Ugarte-Gil C, Guerra Gronerth RI, Lucchetti A, Grogl M, Gotuzzo E. Hydroxychloroquine to prevent SARS-CoV-2 infection among healthcare workers: early termination of a phase 3, randomised, open-label, controlled clinical trial. BMC Res Notes. 2023; 16(1):22.
• Schwalb A, Emery JC, Dale KD, Horton KC, Ugarte-Gil CA, Houben RMGJ. Impact of Reversion of Mycobacterium tuberculosis Immunoreactivity Tests on the Estimated Annual Risk of Infection. Am J Epidemiol. 2023: kwad028.
• Pehrson I, Sayyab S, Das J, Idh N, Paues J, Méndez-Aranda M, Ugarte-Gil C, Lerm M. The spectrum of tuberculosis described as differential DNA methylation patterns in alveolar macrophages and alveolar T cells. Clin Epigenetics. 2022; 14(1):175.
• Jaramillo-Valverde L, Levano KS, Tarazona DD, Vasquez-Dominguez A, Toledo-Nauto A, Capristano S, Sanchez C, Tarazona-Santos E, Ugarte-Gil C, Guio H. GSTT1/GSTM1 Genotype and Anti-Tuberculosis Drug-Induced Hepatotoxicity in Peruvian Patients. Int J Mol Sci. 2022; 23(19):11028

More Publications